Home | Contact us | Disclaimer
A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

Study Design

• Patient population: 24 Down Syndrome patients 18 to 45 years of age without dementia
• 4-week treatment phase
• First patient dosed in September 2013
• Status: COMPLETED [Link to Press Release]

Primary Outcome Measures

• Incidence of adverse events
• Changes from Baseline in physical and neurological examinations

For more information on this trial, please visit: Clinical Trials
© 2015 Transition Therapeutics Inc.